SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission file number: 001-35223
BioLineRx Ltd.
(Translation of registrant’s name into English)
2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On November 17, 2026, BioLineRx Ltd. (the “Company”)
entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with SCOF Motixafortide Holdings, Inc., a Delaware
corporation and an affiliate of Soleus Capital Management, L.P. (the “Purchaser”), pursuant to which the Company agreed to
sell to the Purchaser a portion of its right to receive future royalty payments on net sales of APHEXDA® (motixafortide) under the
Company’s License Agreement with Ayrmid Pharma Ltd. (“Ayrmid”), dated November 20, 2024, as amended (the “Ayrmid
License”). The transaction is expected to close on or about November 30, 2026, subject to the satisfaction of customary closing
conditions.
Pursuant to the Purchase Agreement, the Company
will sell to the Purchaser, at closing, 80% of the royalty payments payable to the Company under the Ayrmid License attributable to sales
occurring on or after the closing date, together with related rights, including amounts payable in respect of any underpayment or late
payment of such royalties, amounts payable in lieu thereof, and royalties payable under any replacement license entered into following
a termination of the Ayrmid License (collectively, the “Purchased Receivables”). As a condition to closing, Ayrmid will consent
to the sale and agree to remit the Purchased Receivables directly to the Purchaser. The Company will retain the remaining 20% of such
royalty payments. Based on the 18% royalty rate payable to the Company under the Ayrmid License, the 80% interest to be sold to the Purchaser
corresponds to a 14.4% royalty on net sales of APHEXDA, and the 20% interest to be retained by the Company corresponds to a 3.6% royalty
on net sales, which retained portion is attributable to the royalties the Company is obligated to pay to Biokine Therapeutics Ltd., the
original licensor of motixafortide to the Company, under the Company’s upstream license agreement with Biokine.
In consideration for the Purchased Receivables,
the Purchaser will pay the Company a one-time purchase price of $5.6 million at closing, less the Purchaser’s documented reasonable
transaction expenses capped at $100,000. The Company will retain, among other things, all rights to receive potential future milestone
payments under the Ayrmid License.
In addition, Kreos Capital VII Aggregator SCSp
(“Kreos”), an affiliate of BlackRock and the lender under the Company’s loan agreement dated September 14, 2022, as
amended (the “Loan Agreement”), has consented to the transaction and agreed to release its security interest in the Purchased
Receivables. In connection with such consent, the Company and Kreos will enter into a Second Amendment to the Loan Agreement at the closing
of the Purchase Agreement (the “Loan Amendment”), pursuant to which the Company will make a partial loan prepayment to Kreos
of $3.0 million at such closing. Following such prepayment, the remaining outstanding amount under the Loan Agreement of approximately
$2.0 million will be repaid in accordance with a new repayment schedule, the minimum cash balance covenant under the Loan Agreement of
$4.0 million will be eliminated, and an amendment to the Company’s floating charge in favor of Kreos will become effective.
The Purchase Agreement contains customary representations,
warranties and covenants of the parties for a transaction of this nature, as well as customary closing conditions.
Chardan Capital Markets, LLC acted as financial
advisor to the Company in connection with the transaction described herein and will receive a financial advisory fee of approximately
$0.4 million, payable upon the closing of the transaction.
The Company intends to use the net proceeds of
the transaction, if consummated, to support its ongoing research and development activities, including the clinical development of GLIX1,
as well as for working capital and general corporate purposes, including the partial repayment of the Loan Agreement described above.
The foregoing description of the Purchase Agreement
is not complete and is qualified in its entirety by reference to the full text of such document, a copy of which is filed as Exhibit 10.1
to this Report on Form 6-K and is incorporated by reference herein.
On November 18, 2026, the Company issued a press
release entitled “BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital.” A copy of the
press release is attached hereto as Exhibit 99.1.
This Report on Form 6-K, including all exhibits
hereto (other than the press release attached as Exhibit 99.1), is hereby incorporated by reference into all effective registration statements
filed by the registrant under the Securities Act of 1933.
Attached hereto and incorporated by reference herein are the following
exhibits:
| Exhibit No. |
|
Description |
| |
|
|
| 10.1(1) |
|
Purchase and Sale Agreement, dated as of November 17, 2026, between
BioLineRx Ltd. and SCOF Motixafortide Holdings, Inc. |
| |
|
|
| 99.1 |
|
Press Release dated November 18, 2026 |
(1)
Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K. The Registrant undertakes to furnish
a copy of all omitted schedules and exhibits to the SEC upon its request.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
BioLineRx Ltd. |
|
| |
|
|
|
| |
By: |
/s/ Philip A. Serlin |
|
| |
|
Philip A. Serlin |
|
| |
|
Chief Executive Officer |
|
Dated: November 18, 2026
Exhibit 99.1
For Immediate Release
BioLineRx
Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
- Transaction
provides non-dilutive capital through sale of BioLineRx's portion
of future
APHEXDA royalties -
- Funds
to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is
currently enrolling the fourth of five
planned dosing cohorts -
- BioLineRx
retains rights to future commercial milestone payments under its existing
license
agreement with Ayrmid -
TEL AVIV, Israel, November 18, 2026 –
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare
diseases, today announced that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA®
(motixafortide) to Soleus Capital Management, L.P. and its affiliates (“Soleus”) for a one-time payment of $5.6 million.
Under the terms of the agreement, Soleus will
acquire BioLineRx's 14.4% royalty interest in future net sales of APHEXDA under the Company's existing license agreement with Ayrmid Pharma
Ltd. (“Ayrmid”). The transaction excludes the remaining 3.6% royalty interest attributable to the original licensor of motixafortide
to BioLineRx, which will continue to retain its interest in the royalty stream. BioLineRx has retained its rights to receive potential
commercial milestone payments under the Ayrmid agreement, as well as royalty payments attributable to periods prior to the closing of
the transaction.
“This transaction enables us to immediately
unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial
milestone payments,” said Philip Serlin, Chief Executive Officer of BioLineRx. “Importantly, the non-dilutive capital will
provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical
trial in glioblastoma and other solid tumors. We believe this transaction represents an attractive, non-dilutive financing solution for
our company and our shareholders.”
“We are pleased to partner with BioLineRx
on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA,” said
Benjamin Lund, Partner at Soleus Capital. “We believe APHEXDA represents a differentiated treatment option in stem cell mobilization
for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement.”
BioLineRx intends to use the proceeds to support
its ongoing research and development activities, including the clinical development of GLIX1, as well as for working capital and general
corporate purposes, including a partial loan repayment to BlackRock EMEA Venture and Growth Lending. In connection with the partial loan
repayment, the Company’s minimum cash balance requirement under the loan agreement (currently $4 million) will be eliminated. The
transaction is expected to close on or about November 30, 2026.
About APHEXDA® (motixafortide)
APHEXDA is a CXCR4 antagonist approved by the
U.S. Food and Drug Administration for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral
blood for collection and subsequent autologous stem cell transplantation in patients with multiple myeloma. APHEXDA is being commercialized
by Ayrmid globally, except in Asia, where it is partnered with Gloria Biosciences.
About BioLineRx
BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical
company pursuing life-changing therapies in oncology and rare diseases. The Company’s lead development asset is GLIX1, a first-in-class,
oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been
initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA®
(motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being
commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide
in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration
with Columbia University.
Learn more about who we are, what we do, and
how we do it at www.biolinerx.com, or on LinkedIn.
About Soleus Capital
Soleus Capital is an investment firm based in
Greenwich, CT focused on the innovative areas of life sciences, including biopharmaceuticals, medical technologies, life sciences tools
and diagnostics. With approximately $3.5 billion in total assets under management as of June 30, 2026, Soleus Capital invests across
the healthcare lifecycle from developmental-stage through commercial, and partners with life science companies across the capital structure
with hedge fund, private equity and structured credit vehicles.
Forward Looking Statement
Various statements in this release concerning
BioLineRx's future expectations constitute “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements include words such as “anticipates,” “believes,” “could,” “estimates,”
“expects,” “intends,” “may,” “plans,” “potential,” “predicts,”
“projects,” “should,” “will,” and “would,” and describe opinions about future events.
These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the consummation and
expected benefits of the royalty monetization transaction with Soleus Capital; BioLine’s receipt and intended use of the transaction
proceeds; the completion and expected effects of the partial repayment of BioLine’s outstanding loan facility, including the elimination
of the minimum cash balance requirement; the future commercial performance, market uptake and net sales of APHEXDA; potential future royalty
and commercial milestone payments relating to APHEXDA; the ongoing Phase 1/2a clinical trial of GLIX1, including its enrollment, progress
and the timing and results of any clinical readout; and BioLineRx’s business strategy, financial position and financing requirements..
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance
or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such
forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in
such forward-looking statements include, but are not limited to: the clinical development, commercialization and market acceptance of
GLIX1 and motixafortide including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for
autologous transplantation in multiple myeloma patients; the initiation, timing, progress and results of BioLineRx’s preclinical
studies, clinical trials and other therapeutic candidate development efforts; BioLineRx’s ability to advance GLIX1 and motixafortide
into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results for GLIX1
and motixafortide will be predictive of real-world results; BioLineRx’s receipt of regulatory approvals for GLIX1 and motixafortide
and the timing of other regulatory filings and approvals; whether access to GLIX1 and motixafortide is achieved in a commercially viable
manner and whether GLIX1 and motixafortide receives adequate reimbursement from third-party payors; BioLineRx’s ability to establish,
manage, and maintain corporate collaborations, as well as the ability of BioLineRx’s collaborators to execute on their development
and commercialization plans; BioLineRx’s ability to integrate new therapeutic candidates and new personnel, as well as new collaborations;
the interpretation of the properties and characteristics of BioLineRx’s therapeutic candidates and of the results obtained with
its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx’s business model and strategic
plans for its business and therapeutic candidates; the scope of protection that BioLineRx’s is able to establish and maintain for
intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual
property rights of others; estimates of BioLineRx’s expenses, future revenues, capital requirements and its need for and ability
to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or
elsewhere; competitive companies, technologies and BioLineRx’s industry; BioLineRx’s ability to maintain the listing of its
ADSs on Nasdaq; statements as to the impact of the political and security situation in Israel on BioLineRx’s business which may
exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the “Risk Factors”
section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2026. In
addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements
unless required by law.
Contacts:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com